AIM
FLNA

Axiom Investment Management’s Filana Therapeutics FLNA Stock Holding History

Axiom Investment Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200
Closed -$8K – 361
2022
Q3 		$8K Buy
+200
New +$5.4K 0.02% 270

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Axiom Investment Management's FLNA Position: Q4 2022 in Review

Axiom Investment Management sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 200 shares — an estimated $8K sold.

Axiom Investment Management first reported a position in FLNA in Q3 2022 and held it in 1 quarter. The position peaked at $8K in Q3 2022. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

  • Axiom Investment Management reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Axiom Investment Management sold 200 Filana Therapeutics shares in Q4 2022, an estimated $8K.
  • Axiom Investment Management first reported a position in Filana Therapeutics in Q3 2022 and held it in 1 quarter.
  • Axiom Investment Management's Filana Therapeutics position peaked at $8K in Q3 2022.
  • 153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on Axiom Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.